[go: up one dir, main page]

AU2001267421A1 - Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders - Google Patents

Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders

Info

Publication number
AU2001267421A1
AU2001267421A1 AU2001267421A AU6742101A AU2001267421A1 AU 2001267421 A1 AU2001267421 A1 AU 2001267421A1 AU 2001267421 A AU2001267421 A AU 2001267421A AU 6742101 A AU6742101 A AU 6742101A AU 2001267421 A1 AU2001267421 A1 AU 2001267421A1
Authority
AU
Australia
Prior art keywords
ht1a
compounds
cns disorders
treating cns
agonistic action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267421A
Other languages
English (en)
Inventor
Roelof W. Feenstra
Stephen K. Long
Johannes A. M. Van Der Heijden
Gustaaf J.M. Van Scharrenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of AU2001267421A1 publication Critical patent/AU2001267421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001267421A 2000-05-12 2001-05-10 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders Abandoned AU2001267421A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00201704 2000-05-12
EP00201704 2000-05-12
PCT/EP2001/005319 WO2001085168A1 (fr) 2000-05-12 2001-05-10 Utilisation de composes presentant une combinaison des activites de l'agoniste du recepteur adrenergique alpha, de la dopamine d2 et du 5-ht1a, pour le traitement de troubles du systeme nerveux central

Publications (1)

Publication Number Publication Date
AU2001267421A1 true AU2001267421A1 (en) 2001-11-20

Family

ID=8171490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267421A Abandoned AU2001267421A1 (en) 2000-05-12 2001-05-10 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders

Country Status (6)

Country Link
US (1) US20030186838A1 (fr)
EP (1) EP1284731A1 (fr)
JP (1) JP2003532676A (fr)
AU (1) AU2001267421A1 (fr)
CA (1) CA2405758A1 (fr)
WO (1) WO2001085168A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405971C (fr) * 2000-05-12 2010-03-30 Solvay Pharmaceuticals B.V. Nouveaux composes de piperazine et de piperidine
EP1408976B3 (fr) * 2001-07-20 2010-08-25 Psychogenics Inc. Traitement des troubles de deficit de l'attention/hyperactivite
WO2004000837A1 (fr) * 2002-06-25 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Nouveau derive de benzoxazolinone
EP1595542A1 (fr) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Administration iontophoretique de composés piperazinyl-2(3h)-benzoxazoloniques
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190472B1 (fr) * 1984-12-21 1989-07-12 Duphar International Research B.V Médicaments à activité antipsychotique
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
NZ331860A (en) * 1996-03-29 2000-04-28 Duphar Int Res Piperazine and piperidine compounds with affinity for both dopamine D2 and seratonin 5-HT1A receptors
EP0900792B1 (fr) * 1997-09-02 2003-10-29 Duphar International Research B.V Dérivés de pipéridine et de pipérazine comme agonistes du récepteur 5-HT1
FR2769912B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
GB9811879D0 (en) * 1998-06-03 1998-07-29 Knoll Ag Therapeutic agents
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives

Also Published As

Publication number Publication date
CA2405758A1 (fr) 2001-11-15
JP2003532676A (ja) 2003-11-05
WO2001085168A1 (fr) 2001-11-15
US20030186838A1 (en) 2003-10-02
EP1284731A1 (fr) 2003-02-26

Similar Documents

Publication Publication Date Title
WO2001041701A3 (fr) Combinaison d'un inhibiteur du recaptage de la serotonine et d'un antagoniste, d'un agoniste inverse ou d'un agoniste partiel de 5-ht¿2c?
WO2001078702A3 (fr) Procedes et compositions de modulation de l'activite des recepteurs adrenergiques alpha
AU9411701A (en) Combination use of acetylcholinesterase inhibitors and gaba<sub>A</sub> inverse agonists for the treatment of cognitive disorders
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
AU2001271567A1 (en) Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
AU2003226014A1 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU3691301A (en) Treatment of fluorocarbon feedstocks
WO2001078703A3 (fr) Methodes et compositions destinees a moduler l'activite des recepteurs adrenergiques alpha
DE60122630D1 (de) Titanoxid sowie Photokatalysator und Photokatalysatorbeschichtungszusammensetzung, die diese verwenden
IL159067A0 (en) METHODS FOR PREPARATION AND USE OF 1alpha,24 (S) -DIHYDROXYVITAMIN D2
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2001236868A1 (en) Ophthalmic use of alpha adrenergic blocking agents
AU2001267421A1 (en) Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
EP1392280A4 (fr) Ethers arylsulfonamide et techniques d'utilisation de ces composes
WO2002051848A3 (fr) Sulfamidothienopyrimidines
AU2874901A (en) Treatment of fluorocarbon feedstocks
WO2002041894A3 (fr) Utilisation d'agonistes selectifs des recepteur d4 de la dopamine dans le traitement de dysfonctions sexuelles
AU3399401A (en) Treatment of fluorocarbon feedstocks
MXPA02001797A (es) BANDA DE SUJECION DE TIPO DE EXPANSION CARACTERIZADA POR UN DISEnO SIMPLIFICADO Y FACILIDAD DE USO.
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
MXPA03004341A (es) Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina.
AU2000270300A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1315499A4 (fr) Compositions et methodes destinees au traitement des troubles anorectaux
MXPA03006970A (es) Nuevo uso de iloperidona.